Compare NGNE & CCSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | CCSI |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.9M | 683.1M |
| IPO Year | 2014 | 2022 |
| Metric | NGNE | CCSI |
|---|---|---|
| Price | $30.98 | $35.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $63.57 | $37.50 |
| AVG Volume (30 Days) | ★ 234.1K | 144.7K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.93 | N/A |
| EPS | N/A | ★ 2.72 |
| Revenue | N/A | ★ $349,696,000.00 |
| Revenue This Year | N/A | $3.33 |
| Revenue Next Year | N/A | $2.70 |
| P/E Ratio | ★ N/A | $13.41 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $20.20 |
| 52 Week High | $43.66 | $41.40 |
| Indicator | NGNE | CCSI |
|---|---|---|
| Relative Strength Index (RSI) | 41.25 | N/A |
| Support Level | $31.20 | N/A |
| Resistance Level | $33.99 | N/A |
| Average True Range (ATR) | 1.95 | 0.00 |
| MACD | -0.47 | 0.00 |
| Stochastic Oscillator | 20.29 | 0.00 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.